Europe Renal Biomarkers Market

Europe Renal Biomarkers Market Size (2022 to 2027):

The size of the European Renal Biomarkers market was valued at USD 326.72 Million in 2022 and is expected to reach USD 447.12 Million by 2027, forecasted to grow at a prominent CAGR of 6.48% during the forecast period. Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period.

The uplift in research and development activities for renal biomarkers, rising healthcare infrastructure, and escalating medical tourism impels the renal biomarkers market growth in Europe. 

Growing pediatric suffering from renal diseases and government supports with funds are driving the market growth. The renal biomarkers market growth is driven by factors like the rising geriatric population and increasing demand for innovative healthcare products. Extensive usage in different diagnostic processes at reasonably low cost is commanding the growth of renal biomarkers in Europe. A high amount spent by the population on healthcare, development of personalized medicine for treating chronic kidney diseases, and early diagnosis of renal cancer may stop disease progression, which in turn escalates the renal biomarkers market growth in the region during the analysis period.

Difficulties associated with regulatory bodies and low reimbursement schemes are the factors impeding the market growth in Europe. No proper way or sufficient identification for examining acute and chronic kidney diseases is hampering the European renal biomarkers market.

This research report on the Europe Renal Biomarkers Market has been segmented and sub-segmented into the following categories:

By Diagnostic Technique:

• Chemiluminescent Enzyme Immunoassay
• Colorimetric Assay
• Enzyme-Linked Immunosorbent Assay
• Liquid Chromatography-Mass Spectrometry
• Particle-Enhanced Turbidimetric Immunoassay

By Type:

• Up-Regulated Proteins
• Interleukin 18
• Kidney injury molecule 1
• Neutrophil gelatinase-associated lipocalin
• Functional Biomarker
• Serum Creatinine
• Serum Cystatin C
• Urine Albumin

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Regional Analysis:

The market size of the renal biomarkers in Europe is estimated to grow with a high CAGR during the historical period from 2022 to 2027. Factors like the rising incidence of chronic kidney diseases like Acute Kidney Injury (AKJ), nephropathies, and drug-induced kidney toxicities leading to the enhancement of new renal biomarkers in regulating disease progression rate. The increasing occurrence rate of renal diseases and high blood pressure is escalating the growth of the market.

The UK is top in the region with the largest market share because of quick introduction and innovations in the market and equipment domain. A considerable increase in the aging population and booming dominance of disease illness, and a thriving interest in innovative work and investments in R&D will propel the market further.  

Germany, France, Italy, and the rest of Europe are anticipated to have subsequent growth in the market of the region due to quick advances in genetics that tends to the development of advanced renal biomarkers in treating kidney diseases, strengthening the increase in the area.

Prominent Companies dominating the Europe Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.